多発性骨髄腫における多剤併用療法(Modified M-2 Protocol)の治療成績

抄録

Twenty patients with multiple myeloma were treated with a combination chemotherapy, consisting of melphalane, cyclophosphamide, ACNU, vincristine, and prednisolone (modified M-2 protocol). Twelve of 20 patients had no prior treatment, while 8 of 20 had been resistant to melphalane or cyclophosphamide.
A good response was obtained in 11 of 20 cases (55%), and a limited response in 5 of 20 cases (25%). The response rate was 80% in total cases. The response rate in the patients with high tumor mass (Stage III) was higher than that with low tumor mass (Stage I, II).
Modified M-2 protocol appered to be effective not only as induction therapy for high tumor mass patients, but also for such patients as resistant to melphalane-prednisolone.